secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0001140361-22-042849
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics receives Nasdaq deficiency notice for insufficient stockholders' equity
--------------------------------------------------------------------------------

- Stockholders' equity ~$8.8M as of Sep 30, 2022, below $10M minimum for Nasdaq Global Market.
- Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Company may also consider transferring its listing from Nasdaq Global Market to Nasdaq Capital Market.
- Notice has no immediate effect on listing; delisting risk if compliance not regained within prescribed timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122042849/0001140361-22-042849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122042849/brhc10044625_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-042849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer